Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
US8426587B2 · kind B2 · utility
7Cited by
42References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2008 |
| Grant date | Apr 23, 2013 |
| Priority date | — |
| Expiry date | Apr 29, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.